Osaka University Venture Capital
VC Fund
Osaka, Japan
Osaka University Venture Capital is a venture capital firm that focuses on early-stage ventures in the fields of life innovation, green innovation, and platform technology. The firm was founded in 2014 and based in Osaka, Japan.
- Total investments:
- 93
- Last investment:
- Lead investor:
- 34%
- Fund size:
- $92M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Osaka University Venture Capital invests in
Stages Osaka University Venture Capital invests in
Countries Osaka University Venture Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $480k–$4.5M
- Series A
- $1.5M–$19M
- Venture - Series Unknown
- $751k–$3.5M
Investment Focus
Industry
- Biotechnology 17 (18%)
- Health Care 15 (16%)
- Medical 12 (13%)
- Manufacturing 12 (13%)
- Therapeutics 8 (9%)
Stage
- Seed 21 (23%)
- Venture - Series Unknown 20 (22%)
- Series A 16 (17%)
- Series B 9 (10%)
- Funding Round 8 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hayami Shimizu
Founder & CEO
|
Founder & CEO | Total investments: 2 | Find email | |
|
Toshiaki Jimbo
President and CEO
|
President and CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer . | $44M / Series A / Sep 15, 2026 | ||
| JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication. | $2M / Jun 18, 2026 | ||
| Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia. Toregem BioPharma is headquartered in Kyoto, Japan. | $5.3M / Series C / May 19, 2026 | ||
| Orbital is a space tech company that provides space debris business to remove debris and a satellite LiDAR business to provide surface data. | $19.2M / Series A / Mar 19, 2026 | ||
| A-Wave is a manufacturing company that develops and markets medical devices, pharmaceuticals, computer software, and hardware. | $3.5M / Series B / Feb 17, 2026 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.6M / Series B / Oct 07, 2025 | ||
| 3DC develops and manufactures a new carbon material, graphene meso sponge (GMS), for electrodes in next-generation batteries, capacitors, fuel cells and other energy storage and generation devices. | $16.7M / Series A / Aug 04, 2025 | ||
| A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions. | $15M / Series A / Jul 07, 2025 | ||
| Thinker provides sales of proximity sensors and proposed solutions using these products. | $3.5M / Venture - Series Unknown / Jul 01, 2025 | ||
| EX-Fusion develops the first commercial laser based nuclear fusion reactor for power generation. | $16M / Series A / Jun 05, 2025 | ||
| See all 93 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Osaka University Venture Capital invest in?
Osaka University Venture Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Venture - Series Unknown stage. Most of the 93 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Osaka University Venture Capital's check size?
Osaka University Venture Capital typically joins rounds of $480k–$4.5M at Seed, $1.5M–$19M at Series A and $751k–$3.5M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Osaka University Venture Capital participates in.
How do I contact Osaka University Venture Capital?
Public channels for Osaka University Venture Capital include the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Osaka University Venture Capital?
The team at Osaka University Venture Capital includes Hayami Shimizu (Founder & CEO) and Toshiaki Jimbo (President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
